2 Million+
Patients served
200,000+
5-star Reviews
12+
Years in operation
300+
Team members and growing
Book Online
Modern. Clean. Extended hours.
Coverage depends on your exact plan, clinician, location and service. Check participation and expected charges with the clinic and your insurer before booking.
Hicksville, NY
Ask the chosen location whether it can arrange the prescribed tablets and professional subcutaneous injections, review HIV tests and coordinate future visits. Bring prior PrEP/PEP dates and discuss travel between locations or states before starting. Confirm which clinician receives pending RNA and confirmatory results and manages interruptions. A convenient neighborhood is useful only if the supply and follow-up pathway fits your plan. A published address does not verify stock, an injection slot or plan approval. If you need another site, get a coordinated referral and preserve prevention while the move is arranged.
Yeztugo is lenacapavir for prevention of sexually acquired HIV-1 in people who do not have HIV. Treatment starts with injections and tablets, then continues with injections about every six months. It can suit someone who prefers fewer medication visits, provided testing and follow-up remain reliable. Twice-yearly medication does not mean twice-yearly attention to every health concern: a new exposure, symptoms, STI screening or a medication change can require contact sooner.
Lenacapavir blocks several stages of HIV replication by acting on the viral capsid. Yeztugo is the prevention product. Sunlenca contains the same active medicine but is used with other antiretrovirals for selected people with HIV whose prior treatments have not worked. The brands and care pathways are not interchangeable. Yeztugo alone must not be used as HIV treatment.
The approved PrEP indication is for adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV through sex. HIV-negative status must be established. Recent exposure, acute viral symptoms, past PrEP/PEP, pregnancy or breastfeeding and all current medicines belong in the evaluation. HIV testing is required before starting and before each injection. A positive or unknown HIV status prevents use as PrEP.
At initiation, a negative antigen/antibody test is confirmed with HIV RNA testing, even if RNA returns after treatment starts. Before continuation, a negative rapid antigen/antibody test requires confirmation with a more sensitive assay. The clinician determines the complete testing approach and reviews symptoms and any ambiguous results.
Provide every prescription, over-the-counter medicine and supplement. Some strong or moderate CYP3A inducers require additional clinician-directed dosing under the August 2026 label; other starting combinations have no recommended regimen. Your prescriber must review the actual medicines and sequence.
The labeled start includes two subcutaneous injections and oral tablets on the first day, followed by oral tablets the next day. Those tablets are part of required initiation, not an optional tolerability trial. A trained professional administers the injections.
Continuation injections are scheduled every 26 weeks with a two-week allowance on either side. Agree on HIV testing, STI screening and what to do before travel or an access delay.
Bring previous HIV and STI results, your current prevention regimen, last injection date if applicable and insurance information. Ask how the next-day tablets will be obtained and how to contact the team if you cannot take them. Confirm medication receipt and testing arrangements before an administration visit. The label describes abdominal injections and an alternative thigh site; the administrator chooses an appropriate site using the current instructions.
The boxed warning concerns resistance if Yeztugo is used during undetected HIV. Report possible acute HIV symptoms immediately rather than waiting for a routine dose. Injection pain, swelling or nodules can occur; some nodules last a long time. Seek urgent care for severe allergic symptoms or a rapidly worsening injection-site reaction. Lenacapavir can affect other medicines long after the last injection, so tell future prescribers when you received it.
Call before an injection is overdue. An authorized oral bridge may be used for some planned delays, but the tablets are not a patient-designed substitute for injections. Longer gaps without bridging can require repeating initiation after reassessment. After stopping, residual drug may remain for 12 months or longer. Your clinician plans ongoing HIV testing and alternative prevention while levels decline.
Ask separately about tablet coverage, injectable medication coverage, laboratory testing and administration charges. The supply may require authorization and shipment to an administration site. Assistance programs have eligibility rules and do not prove that a particular clinic or insurer participates. Keep a written transition plan while these steps are completed; confirm actual availability before traveling to a listed location.
Nao Medical Hicksville: 232 W Old Country Rd, Hicksville, NY 11801. Call +1-917-310-3371 to confirm the specific service, clinician and appointment before travelling.
Contact the clinic to confirm this service, the clinician and appointment preparation. General clinic hours may differ from service appointment times.
YEZTUGO administration should be confirmed before a visit. The right location is one that can support testing, medication receipt, trained staff, storage requirements, scheduling, and six-month follow-up for that patient's plan.
Coverage depends on your exact plan, clinician, location and service. Check participation and expected charges with the clinic and your insurer before booking.
Bronx
932 E 174th St, Bronx, NY 10460
A Bronx clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in West Farms, Crotona Park East, and nearby Bronx neighborhoods.
View location details Get directions
Queens
37-15 23rd Ave, Astoria, NY 11105
A Queens clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods.
View location details Get directions
Bronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods.
View location details Get directions
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A Brooklyn clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods.
View location details Get directions
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A Queens clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods.
View location details Get directions
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A Queens clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods.
View location details Get directions
Queens
30-07 36th Ave, Astoria, NY 11106
A Queens clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods.
View location details Get directions
Long Island
135 Mineola Blvd, Mineola, NY 11501
A Long Island clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in Mineola, Garden City, Westbury, and nearby Nassau County communities.
View location details Get directions
Manhattan
259 1st Ave, New York, NY 10003
A Manhattan clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in StuyTown, East Village, Gramercy, and nearby Manhattan neighborhoods.
View location details Get directions
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A Brooklyn clinic that can help patients ask about YEZTUGO availability, coverage support, and PrEP follow-up, serving patients in Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods.
View location details Get directionsReview starter dosing, six-month scheduling, testing, and shipment timing before choosing the next step.
Confirm whether the medication path, testing, coverage, and appointment timing can be coordinated.
Coverage review can clarify prior authorization, payer routing, and Advancing Access support.
Choose a convenient NYC or Long Island clinic and confirm what is needed before booking.
APRETUDE may be relevant for patients who want an established long-acting PrEP option while asking about YEZTUGO access.
HIV and STD testing visits can support immediate testing, follow-up, and broader sexual-health questions.
Arrange an evaluation to discuss suitable care, preparation and follow-up with a clinician.
Call care teamBook a Yeztugo first visit Call (917) 310-3371
Eligibility, testing and what to bring · Side effects and safety · Starter doses and return visits
Ask the selected service for the next available appointment for YEZTUGO PrEP assessment. Confirm whether booking or a walk-in visit is appropriate before traveling. The first visit reviews eligibility, records and the treatment plan. Medication delivery, authorization and an injection appointment may need separate coordination.
Bring previous HIV and STI results, your current prevention regimen, last injection date if applicable and insurance information. Ask how the next-day tablets will be obtained and how to contact the team if you cannot take them. Confirm medication receipt and testing arrangements before an administration visit. The label describes abdominal injections and an alternative thigh site; the administrator chooses an appropriate site using the current instructions.
At initiation, a negative antigen/antibody test is confirmed with HIV RNA testing, even if RNA returns after treatment starts. Before continuation, a negative rapid antigen/antibody test requires confirmation with a more sensitive assay. The clinician determines the complete testing approach and reviews symptoms and any ambiguous results.
Provide every prescription, over-the-counter medicine and supplement. Some strong or moderate CYP3A inducers require additional clinician-directed dosing under the August 2026 label; other starting combinations have no recommended regimen. Your prescriber must review the actual medicines and sequence.
The labeled start includes two subcutaneous injections and oral tablets on the first day, followed by oral tablets the next day. Those tablets are part of required initiation, not an optional tolerability trial. A trained professional administers the injections.
Continuation injections are scheduled every 26 weeks with a two-week allowance on either side. Agree on HIV testing, STI screening and what to do before travel or an access delay.
Ask separately about tablet coverage, injectable medication coverage, laboratory testing and administration charges. The supply may require authorization and shipment to an administration site. Assistance programs have eligibility rules and do not prove that a particular clinic or insurer participates. Keep a written transition plan while these steps are completed; confirm actual availability before traveling to a listed location.
Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.
Yeztugo is lenacapavir for prevention of sexually acquired HIV-1 in people who do not have HIV. Treatment starts with injections and tablets, then continues with injections about every six months. It can suit someone who prefers fewer medication visits, provided testing and follow-up remain reliable. Twice-yearly medication does not mean twice-yearly attention to every health concern: a new exposure, symptoms, STI screening or a medication change can require contact sooner.
At initiation, a negative antigen/antibody test is confirmed with HIV RNA testing, even if RNA returns after treatment starts. Before continuation, a negative rapid antigen/antibody test requires confirmation with a more sensitive assay. The clinician determines the complete testing approach and reviews symptoms and any ambiguous results.
Provide every prescription, over-the-counter medicine and supplement. Some strong or moderate CYP3A inducers require additional clinician-directed dosing under the August 2026 label; other starting combinations have no recommended regimen. Your prescriber must review the actual medicines and sequence.
The labeled start includes two subcutaneous injections and oral tablets on the first day, followed by oral tablets the next day. Those tablets are part of required initiation, not an optional tolerability trial. A trained professional administers the injections.
Continuation injections are scheduled every 26 weeks with a two-week allowance on either side. Agree on HIV testing, STI screening and what to do before travel or an access delay.
Call before an injection is overdue. An authorized oral bridge may be used for some planned delays, but the tablets are not a patient-designed substitute for injections. Longer gaps without bridging can require repeating initiation after reassessment. After stopping, residual drug may remain for 12 months or longer. Your clinician plans ongoing HIV testing and alternative prevention while levels decline.
No. Oral tablets on both initiation days are part of the labeled regimen. Contact your clinician immediately if the second-day tablets are unavailable, missed or vomited; do not improvise replacement doses.
The exact plan must be checked for both formulations, the dispensing route and administration site. Also ask about visits and laboratory charges. Another person’s approval or copay is not a reliable estimate of yours.
A clinician can compare options and make a transition plan based on HIV results, last doses, exposure and interactions. Keep the existing prevention plan until you receive explicit instructions; changing products without coordination can leave a gap.
